About Puretech Health PLC (LON:PRTC)
PureTech Health plc is a cross-disciplinary healthcare company. The Company operates through two segments: growth stage businesses and project phase businesses. Businesses in the growth stage businesses segment are those whose activities focus on developing products to solve healthcare problems in varied markets. This segment includes subsidiary companies, which include Vedanta Biosciences, Inc., Gelesis, Inc., Akili Interactive Lab, Inc., Tal Medical, Inc., Karuna Pharmaceuticals, Inc., Entrega Inc. and Follica Incorporated. Businesses in the project phase businesses segment are those whose activities are focused on financing, sourcing and creating new product candidates and newly created businesses whose technologies are in the process of validation. This segment includes subsidiary companies, which include The Sync Project Inc., Sonde Health, Inc., Commense Inc., Alivio Therapeutics, Inc., Vor Biopharma Inc., Enlight Biosciences, LLC, Mandara Sciences, LLC and Knode Inc.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Biotechnology & Medical Research
- Sub-Industry: N/A
- Symbol: LON:PRTC
- CUSIP: N/A
- Web: puretechhealth.com/
- Market Cap: £297.81 million
- Outstanding Shares: 236,358,000
- 50 Day Moving Avg: GBX 132.94
- 200 Day Moving Avg: GBX 125.86
- 52 Week Range: GBX 110 - GBX 139.75
Sales & Book Value:
- Trailing P/E Ratio: N/A
- P/E Growth: 0.00
- Annual Revenue: £4.85 million
- Price / Sales: 61.40
- Book Value: GBX 0.58 per share
- Price / Book: 2.17
- EBITDA: ($94,050,000.00)
- Net Margins: -10,126.32%
- Return on Equity: -53.32%
- Return on Assets: -47.28%
- Average Volume: 28,474 shs.
Frequently Asked Questions for Puretech Health PLC (LON:PRTC)
What is Puretech Health PLC's stock symbol?
Puretech Health PLC trades on the London Stock Exchange (LON) under the ticker symbol "PRTC."
Where is Puretech Health PLC's stock going? Where will Puretech Health PLC's stock price be in 2017?
5 brokers have issued 12 month target prices for Puretech Health PLC's shares. Their forecasts range from GBX 207 to GBX 259. On average, they anticipate Puretech Health PLC's share price to reach GBX 239 in the next year. View Analyst Ratings for Puretech Health PLC.
Who are some of Puretech Health PLC's key competitors?
Some companies that are related to Puretech Health PLC include Inovio Pharmaceuticals (INO), Mesoblast Limited (MESO), PDL BioPharma (PDLI), TG Therapeutics (TGTX), Adamas Pharmaceuticals (ADMS), Agenus (AGEN), Kala Pharmaceuticals (KALA), Cara Therapeutics (CARA), Celldex Therapeutics (CLDX), Concert Pharmaceuticals (CNCE), Arbutus Biopharma Corporation (ABUS), Idera Pharmaceuticals (IDRA), Codexis (CDXS), Protagonist Therapeutics (PTGX), Corvus Pharmaceuticals (CRVS), NewLink Genetics Corporation (NLNK), Novavax (NVAX) and Curis (CRIS).
Who are Puretech Health PLC's key executives?
Puretech Health PLC's management team includes the folowing people:
- Joichi Ito, Chairman of the Board
- Daphne Zohar, Chief Executive Officer, Co-Founder, Director
- Robert S. Langer Jr., Co-Founder, Non-Executive Director
- Bennett M. Shapiro M.D., Co-Founder, Non-Executive Director
- Bernat Olle Ph.D., Venture Partner
- Michael F. MacLean, Chief Financial Officer, Executive Vice President
- Stephen Muniz, Executive Vice President - Legal, Finance and Operations
- Eric Elenko, Executive Vice President - Science & Technology
- David Steinberg, Executive Vice President - Company Creation
- Joseph B. Bolen Ph.D., Chief Scientific Officer
How do I buy Puretech Health PLC stock?
Shares of Puretech Health PLC and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Puretech Health PLC's stock price today?
MarketBeat Community Rating for Puretech Health PLC (LON PRTC)MarketBeat's community ratings are surveys of what our community members think about Puretech Health PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Puretech Health PLC stock can currently be purchased for approximately GBX 126.
Earnings History for Puretech Health PLC (LON:PRTC)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Puretech Health PLC (LON:PRTC)
Current Year EPS Consensus Estimate: $-0.27 EPS
Dividend History for Puretech Health PLC (LON:PRTC)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Puretech Health PLC (LON:PRTC)Insider Trades by Quarter for Puretech Health PLC (LON:PRTC)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|4/28/2016||Scardino,Dame Marjorie||Insider||Buy||5,000||GBX 135||£6,750|
Headline Trends for Puretech Health PLC (LON:PRTC)
Latest Headlines for Puretech Health PLC (LON:PRTC)
Loading headlines, please wait.
Puretech Health PLC (PRTC) Chart for Sunday, October, 22, 2017